DOCSLIB.ORG

Subject Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subject Index Subject Index A-84543 420(fig.),441 - regulation 182-184 A-85380 420(fig.),441 acute nicotine sensitivity, animal studies A-98593 441 566-572 ABT-089 326-327, 420(fig.), 441 - acute sensitivity, genetics 566-569 ABT-418 231, 326-327, 420(fig.), 800, 802 - tolerance development, genetic ABT-594 420(fig.), 441, 800 influences 569-571 1-acetyl-4-methyl-piperazine 609 addiction 605, 650-654 acetylcholine 13, 420(fig.), 436, 764-765 Addiction Research Center Inventory - release, auto-facilitatory effect 7 (ARCI) 621 - structure 81 (fig.) adenosine triphosphate nicotinic acetylcholine receptor-inducing activity receptor, presynaptic 200 (ARIA) protein 96 adrenalectomy 429 acetylcholine receptors (AChRs) agonist binding site 278-282 - central nervous system 165-176 - ACh binding, structural determinants - features of sequence 85(fig.) 278-279 - nicotinic receptors - nAChR pharmacological profile, -- brain 301-303 allosteric modulation 279-282 -- central nervous system, distribution alcoholism 754 779 allosteric effector 277 -- characterization 82 - voltage-dependent modulation -- decline with ageing 755(table) 292(fig.) -- distribution with respect to allosteric model 275-276 cholinergic neurons 20-25 allosteric modulators, drug candidates -- invertebrates 513-514 487--490 -- isolation 82 allostericaly potentiating ligands 484 -- modulatory control by allostericaly d2 gene acting ligands 483--487 - avian K2 regulatory region 60 -- monitoring, experimental - silencer region 60-61 requirements 338-339 a-3 gene 46--47 -- neuronal, structures 101-146 a-7 gene 45--46 -- presynaptic 7-8,195-196 - bovine a-7 promoter 61-62 --- ganglia 257-258 - chicken a-7 promoter 61 --- pharmacology 195-200 a-7 gene, seizure disorders 576 -- skeletal muscle a-7 receptor, properties 323-325 --- biophysical properties 88-89 a-bungarotoxin (K-bgt) 4,7,89,383, --- functional aspects 81-82 455 --- structure 83-88 - neuromuscular transmission, inhibition -- subtypes 680-681 80 -- upregulation 665-667 a-cobra toxin 89 - neuronal surface 176-182 a-conotoxin AulE 469 - regional distribution, peripheral a-conotoxin Epl 469--470 nervous system 164-165 a-conotoxin Iml 455, 467--468 814 Subject Index a-conotoxin MI 470 -- transgenic analysis 63-64 a-conotoxin MIl 465-467 - neuron restrictive silencer element 64 a-conotoxin PnIAIPnIB and analogues - silencing elements, role of 44-45 469 fJ-4 gene 46-47 a-conotoxins 89 fJ-endorphine concentration 706-707, a-neurotoxin family 89-91 781 Alzheimer's disease 487,755-757, bHLH transcription factors, f33 758-760, 780(table) regulation in retina 47-49 - K-7 selective agonists 133 bilayer reconstructed nAChRs 359- - brain nAChRs 325-326 375 - cognitive dysfunction, nicotine - chick a-6 subtype 370-372 treatment 593-594 - chick a-7, a-8 and a-7-a-8 subtypes - nicotine binding sites, affinity 144 368-370 - nicotine, treatment 594,788-793 - functional channel reconstruction -- amyloid deposition 490 362-363 -- skin patches 588 - insect a-bgt receptors 368 - PET studies of nAChRs 549-554 - lipid bilayers, formation 360 - trans-meta-nicotine 439 - muscle-type receptor 363-367 amacrine cells, retina 17 -- a-2/3 r 8 nAChRs channels Amanita muscaria 79 364-365 amino acid transmitter 708 -- a-2/3 r 8 nAChRs in oocytes 366 amobarbital 428 -- a-2/3 r 8 nAChRs reconstructed in amphetamine 533,609,611 lipid bilayer 365-366 amyloid and neuronal nAChRs 233 - nAChRs subtypes for reconstruction, anabaseine 307, 420(fig.), 439, 609, 801 purification 360-362 analgesia 799-800 - neuronal type receptor 367-372 anatoxin-a 440 brain, age-related degenerative diseases anotoxin 609 754-761 anxiety 802-803 brain nAChRs 272,301-303 anxiogenic drug stimulus 679 - high affinity receptors 315 apolipoprotein E, neuronal nAChRs -low affinity receptors 315 234 brain slice recording 301 APV 349 brainstem 16 arachidonic acid site 430 bromo acetylcholine 84-85 (figs ), 86 atherosclerosis 763 atropine 349,455,484 caffeine 609 attention deficit hyperactivity disorder calbindin 134 587,798-799 calcitonin gene-related peptide 96,328, - nicotine patch administration 594 430 autocrine growth factor 134 calcium influx entry 5 autoreceptors 23-24, 193 calcium, neuronal nAChRs 305-306 - subunit composition 24 calnexin 93 Cam kinase II 204-205 barbiturates 609 carbachol 420(fig.),436 basal telencephalic system 13-15,18- carbamazepine monotherapy 290 19(tables) carbamylcholine 316 basic fibroblast growth factor 228 carotid body, chemosensory cells 164 benzodiazepines 609 CAT 43 benzoquinonium 427 caudate putamen 15 benzylisoquinoline family 80 central nervous system (CNS) /34, a3, as gene cluster 64-65 - AChRs, distribution on the neural fJ-2 gene surface 180-181 - fJ-2 promoter - AChRs, regional distribution 165-176 -- mouse 63 -- chicken brain, mapping 176 Subject Index 815 -- mammals, species differences cyttsme 422(fig.), 435, 609 175-176 cytoprotection 800-802 -- mapping studies 166,173-175 - neuronal nAChRs, functions served D-erythro-sphingosine 204 315-316 d-tubocurarine 41,80-81,316, 422(fig.), CGS-10746B 613-614 456-458 channel domain, schematic - competitive neuromuscular blockade representation 283(fig.) 82 chick ciliary ganglion 255(fig.),257 DBO-083 420(fig.) "chipping" 606 decamethonium 4,422(fig.) chlorisondamine 312, 422(fig.), 674 dementia with Lewy Bodies 232, 757- chlorpromazine 291, 422(fig.), 427 758 choline 436 dependence, definition 604 cholinergic agonists 609 depression 754, 780(table), 802-803 cholinergic channel dexamethasone 429 - modulators 441-442 dihydropyridine, binding site 429-430 -- orders or potency and efficacy discriminative stimulus effects, nicotine 433(table) see nicotine dependence cholinergic neurons dizocilpine 422(fig.),593 - neural tissue 13-20 DMXB 439, 801 - vertebrate species vs. CNS, comparison donepezil 553 between 18-19(tables) dopamine 317,607,681-704 cholinergic systems - desensitization 691-692 - main, mammalian brain 14(fig.) - discriminative stimulus effects of - wiring vs. volume transmission 24-25 nicotine, role of 611-614 cholinesterase inhibitors 553-554 - neurons ciliary neuron, synaptic specialization -- glutamate, role of 689-690 associated with an E15 255(fig.) -- nAChRs (a-7-containing), role of ciliary neurotrophic factor 216 689-690 Cis-acting regulatory elements, -- nAChRs, expression of 681 identification 43-49 -- nAChRs (somato-dendritic), closed-channel trapping 4 inactivation 692-693 CNQX 349 -- nicotine, electrophysiological effects cocaine 533-534,611-612 688-689 cochlear ganglia 17 - nicotine-self administration, role of cognitive function 782-783,787-788 636-639 - behavioural effects 782-783 - nicotinic receptors, presynaptic - role of nAChRs 587-595 196-197 -- animals, laboratory 588-589 - release, nAChRs activation 21 -- humans, effects in 587-588 - studies -- neural basis, cognition 589-592 -- ex vivo 684-688 -- neurotransmitter interactions -- in vitro 682 592-593 -- in vivo 684-688 conditioned taste aversion (CTA) - transmission paradigm 619-620 -- adaptive changes after nicotine conotoxins 383 exposure 690-691 conus venom peptides 464-470 -- sensitization to nicotine 698 cotinine 781 -- tolerance and dependence 693- craving 677 698 critical flicker fusion 794 dorsal root ganglia (DRG) 17 Crohn's disease 765 Down syndrome, nicotinic binding 232 - smoking 145 drug abuse 606 curare 455 duhydro-f3-erythroidine 422(fig.), CYP-2A6 781 456(fig.),458-459 816 Subject Index epibaditine 231,303,328, 420(fig.), 440, - release, nAChRs activation 21 763, 799-800 growth factors 551-552 Epiboxidine 420(fig.) GTS-21 326-327, 420(fig.), 439, 800 epilepsy 753-754, 780(table), 803 - autosomal dominant nocturnal frontal habenulo-interpeduncular tract 14(fig.), lobe epilepsy (ADNFLE) 144,289- 15, 18-19(table) 290,575-576,803 habituation 605 erabutoxin-a 89 haloperidol 594,707,785-786,797 ethanol 533 head injury 754 excitatory postsynaptic potential 81-82 heterologous expression 514-515 exocytosis 203 heteroreceptors 21-23, 193-194 - subunit composition 22-23 facilitation 258 hexamethonium 4,7,312-314,383, fasciculus retroflexus of Meynert 6-7 422(fig.), 620, 650, 754 FK1 427 Hill coefficient 83 FR-lO 645 hippocampal neurons FRAs 708-710 - conventional slices, nicotinic receptors Fyn 205 343-345 - cultured, nicotinic receptors 339-343 GABAergic and glutaminergic synaptic hippocampus transmission, hippocampus 345-348 - CAl field, synaptic transmission by a-7 galanthamine 427 subunit 348-350 y.aminobutyric acid (GABA) 21-22 histrionicotoxin 427,435 - nicotinic receptors, presynaptic 5-HT3 receptor antagonists 687 198-199 human a-3 promoter 66-68 ganglia, autonomic Huntington's disease 786 - AChRs distribution 164--165 hydrocortisone 429 - nAChRs subtypes 247 hydroxycortisone 291 ganglia, nicotinic receptors 5-hydroxytryptamine nicotinic receptors, - composition 248-250 presynaptic 198 - electrophysiological features 249- hypertension 763-764 250 hypothalamus, cholinergic neurons, - immunological identification 248- distribution invertebrate species 18- 249 19(tables) - presynaptic 257-258 ganglion blocking agents 312-314,764 ibogaine 688 ganglionic nicotinic receptors imidacloprid, structure 512(fig.),513 - regulation 258-262 induce fit model 275 -- cell-cell interactions, receptor inflammatory bowel disease 765 regulation 258-259 inhibitory postsynaptic potential 6 -- developmental regulation 259-260 inter alia 6 -- molecular controls 260-262 internodal cells Chara corallina alga 34 ganglionic transmission, nAChRs irreversible pharmacological blockade 247-262 6 GBR-12909 612-613 islands of Calleja 15 gene(s)
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • INSTITUTO DE QUÍMICA – CAMPUS ARARAQUARA Victor De Sousa Batist
    UNIVERSIDADE ESTADUAL PAULISTA “JÚLIO DE MESQUITA FILHO” INSTITUTO DE QUÍMICA – CAMPUS ARARAQUARA Victor de Sousa Batista Estudos de modelagem molecular de compostos bioativos frente ao receptor nicotínico de acetilcolina do subtipo α4β2 Araraquara 2016 Victor de Sousa Batista Estudos de modelagem molecular de compostos bioativos frente ao receptor nicotínico de acetilcolina do subtipo α4β2 Trabalho de Conclusão de Curso apresentado ao Instituto de Química da Universidade Estadual Paulista “Júlio de Mesquita Filho” como parte dos requisitos para a obtenção do título de Bacharel em Química. Orientador: Prof. Dr. Nailton Monteiro do Nascimento Júnior Araraquara 2016 Victor de Sousa Batista Estudos de modelagem molecular de compostos bioativos frente ao receptor nicotínico de acetilcolina do subtipo α4β2 Trabalho de Conclusão de Curso apresentado ao Instituto de Química da Universidade Estadual Paulista “Júlio de Mesquita Filho” como parte dos requisitos para a obtenção do título de Bacharel em Química. Aprovado em _____ de ________________________ de 2016. BANCA EXAMINADORA __________________________________________ Prof. Dr. Nailton Monteiro do Nascimento Júnior Unesp – Araraquara __________________________________________ Prof. Dr. Gustavo Troiano Feliciano Unesp – Araraquara __________________________________________ Profa. Dra. Cíntia Duarte de Freitas Milagre Unesp – Araraquara Araraquara 2016 AGRADECIMENTOS Ao meu orientador, Prof. Dr. Nailton Monteiro do Nascimento Júnior, por sempre me incentivar a ultrapassar meus limites e pela
    [Show full text]
  • Bioorganic & Medicinal Chemistry Letters
    Bioorganic & Medicinal Chemistry Letters 18 (2008) 4651–4654 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl Epiboxidine and novel-related analogues: A convenient synthetic approach and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes Luca Rizzi a, Clelia Dallanoce a,*, Carlo Matera a, Pietro Magrone a, Luca Pucci b, Cecilia Gotti b, Francesco Clementi b, Marco De Amici a a Istituto di Chimica Farmaceutica e Tossicologica ‘‘Pietro Pratesi”, Università degli Studi di Milano, Via Mangiagalli 25, 20133 Milano, Italy b CNR, Istituto di Neuroscienze, Farmacologia Cellulare e Molecolare e Dipartimento Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy article info abstract Article history: Racemic exo-epiboxidine 3, endo-epiboxidine 6, and the two unsaturated epiboxidine-related derivatives Received 18 June 2008 7 and 8 were efficiently prepared taking advantage of a palladium-catalyzed Stille coupling as the key Revised 3 July 2008 step in the reaction sequence. The target compounds were assayed for their binding affinity at neuronal Accepted 4 July 2008 a4b2 and a7 nicotinic acetylcholine receptors. Epiboxidine 3 behaved as a high affinity a4b2 ligand Available online 10 July 2008 (Ki = 0.4 nM) and, interestingly, evidenced a relevant affinity also for the a7 subtype (Ki = 6 nM). Deriva- tive 7, the closest analogue of 3 in this group, bound with lower affinity at both receptor subtypes Keywords: (K = 50 nM for a4b2 and K = 1.6 lM for a7) evidenced a gain in the a4b2 versus a7 selectivity when Neuronal nicotinic acetylcholine receptors i i compared with the model compound.
    [Show full text]
  • Synthesis of Epiboxidine 36
    C H A P T E R - I I Synthesis of Epiboxidine 36 1. Introduction The construction of 7-azabicyclo[2.2.1]heptane framework has seen strong revival immediately after the structural elucidation of epibatidine (1) {exo-2-(6-chloro-3-pyridyl)-7- azabicyclo[2.2.1]heptane}.' Epibatidine (1); the only prominent m e m b e r of this class, as introduced in the previous chapter, has been shown to be a highly potent non-opioid analgesic agent^'® an d a novel nicotinic acetylcholine receptors (nAChRs)^'® agonist. Fig. 1 Although these outstanding pharmacological activities of 1 have kindled interest to recognize this molecule as an useful therapeutically important drug, its high toxicity, * causing death in mice (six out of six) w h e n injected at 10 (iL/ K g scale, has b e c o m e a major impediment in developing this molecule as a drug.® Therefore, there has been continuing research interest towards an alternate p h a r m a c o p h o r e related to the structure 1 capable of exhibiting comparable pharmacological properties but with an enhanced ratio of pharmacological to toxicological activity. In this context, chemists and phamacologists have begun synthesizing compounds analogous to 1 by • altering, extending or cleaving the 7-azabicyclo[2.2.1]heptane framework of 1, keeping the pyridyl ring intact, • adding extra functionalities in the original framework of 1 along with the features described above or, • by combining structural features of the k n o w n alkaloids having high affinity towards nicotinic receptors an d 1.
    [Show full text]
  • Review 0103 - 5053 $6.00+0.00
    http://dx.doi.org/10.5935/0103-5053.20150045 J. Braz. Chem. Soc., Vol. 26, No. 5, 837-850, 2015. Printed in Brazil - ©2015 Sociedade Brasileira de Química Review 0103 - 5053 $6.00+0.00 Recent Syntheses of Frog Alkaloid Epibatidine Ronaldo E. de Oliveira Filho and Alvaro T. Omori* Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, 09210-580 Santo André-SP, Brazil Many natives from Amazon use poison secreted by the skin of some colorful frogs (Dendrobatidae) on the tips of their arrows to hunt. This habit has generated interest in the isolation of these toxins. Among the over 500 isolated alkaloids, the most important is undoubtedly (-)-epibatidine. First isolated in 1992, by Daly from Epipedobates tricolor, this compound is highly toxic (LD50 about 0.4 µg per mouse). Most remarkably, its non-opioid analgesic activity was found to be about 200 times stronger than morphine. Due to its scarcity, the limited availability of natural sources, and its intriguing biological activity, more than 100 synthetic routes have been developed since the epibatidine structure was assigned. This review presents the recent formal and total syntheses of epibatidine since the excellent review published in 2002 by Olivo et al.1 Mainly, this review is summarized by the method used to obtain the azabicyclic core. Keywords: epibatidine, organic synthesis, azanorbornanes H Cl H 1. Introduction N N O N N At an expedition to Western Ecuador in 1974, Daly and Myers isolated traces of an alkaloid with potential biological (–)-Epibatidine(1) Epiboxidine(1a) activity from the skin of the species Epipedobastes tricolor.
    [Show full text]
  • Synthesis of Epiboxidine and Various X-Azatricyclo
    [3+2] CYCLOADDITION OF NONSTABILIZED AZOMETHINE YLIDES: SYNTHESIS OF EPIBOXIDINE AND VARIOUS X-AZATRICYCLO[m.n.0.0 a,b]ALKANES A THESIS SUBMITTED TO THE UNIVERSITY OF POONA FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN CHEMISTRY BY AKHILA KUMAR SAHOO Division of Organic Chemistry (Synthesis) National Chemical Laboratory PUNE - 411 008 Acknowledgement I take this opportunity with immense pleasure to express my deep sense of gratitude to my teacher and research guide Dr. Ganesh Pandey, who has helped me a lot to learn and think more about chemistry. I thank him for his excellent guidance, constant encouragement, sincere advice, friendship and unstinted support during all the tough times of my Ph. D. life. I do sincerely acknowledge the freedom rendered to me by him for independent thinking, planning and executing the research. I consider very fortunate for my association with him which has given a decisive turn and a significant boost in my career. I gratefully acknowledge the guidance, training, and support extended by my senior colleague Dr. Trusar D. Bagul during the total tenure of my Ph.D life. Special thanks to all my senior colleagues and my present colleagues Dr. (Mrs.) Gadre, Laha, Nagesh, Murugan, Kapur, Tiwari, Rani, Late Mal, Utpal, Prabal, Srinivas, Sanjay, Balakrishna, and Inderesh for maintaining a warm and a very cheerful atmosphere in the lab. They made working the lab very enjoyable. Special acknowledgements to Laha, Nagesh, Kapur, Tiwari, Amar (Kallu), Raghu (Ingle), Gadre Madam, Utpal, Muruga, Jayanthi and Sreenivas for taking trouble in bringing out the thesis. Help from the spectroscopy and mass groups is gratefully acknowledged.
    [Show full text]
  • Botulinum Toxin
    Botulinum toxin From Wikipedia, the free encyclopedia Jump to: navigation, search Botulinum toxin Clinical data Pregnancy ? cat. Legal status Rx-Only (US) Routes IM (approved),SC, intradermal, into glands Identifiers CAS number 93384-43-1 = ATC code M03AX01 PubChem CID 5485225 DrugBank DB00042 Chemical data Formula C6760H10447N1743O2010S32 Mol. mass 149.322,3223 kDa (what is this?) (verify) Bontoxilysin Identifiers EC number 3.4.24.69 Databases IntEnz IntEnz view BRENDA BRENDA entry ExPASy NiceZyme view KEGG KEGG entry MetaCyc metabolic pathway PRIAM profile PDB structures RCSB PDB PDBe PDBsum Gene Ontology AmiGO / EGO [show]Search Botulinum toxin is a protein and neurotoxin produced by the bacterium Clostridium botulinum. Botulinum toxin can cause botulism, a serious and life-threatening illness in humans and animals.[1][2] When introduced intravenously in monkeys, type A (Botox Cosmetic) of the toxin [citation exhibits an LD50 of 40–56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng needed]; these are some of the most potent neurotoxins known.[3] Popularly known by one of its trade names, Botox, it is used for various cosmetic and medical procedures. Botulinum can be absorbed from eyes, mucous membranes, respiratory tract or non-intact skin.[4] Contents [show] [edit] History Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage").
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • Development of Novel Nicotinic Receptor
    University of New Orleans ScholarWorks@UNO University of New Orleans Theses and Dissertations Dissertations and Theses 8-7-2003 Development of Novel Nicotinic Receptor Mediated Therapeutic Agents: Synthesis and Biological Evaluation of Novel Epibatidine Analogs and the First Total Synthesis of Anabasamine and Related Analogs Stassi DiMaggio University of New Orleans Follow this and additional works at: https://scholarworks.uno.edu/td Recommended Citation DiMaggio, Stassi, "Development of Novel Nicotinic Receptor Mediated Therapeutic Agents: Synthesis and Biological Evaluation of Novel Epibatidine Analogs and the First Total Synthesis of Anabasamine and Related Analogs" (2003). University of New Orleans Theses and Dissertations. 40. https://scholarworks.uno.edu/td/40 This Dissertation is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in University of New Orleans Theses and Dissertations by an authorized administrator of ScholarWorks@UNO. For more information, please contact [email protected]. DEVELOPMENT OF NOVEL NICOTINIC RECEPTOR MEDIATED THERAPEUTIC AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL EPIBATIDINE ANALOGS AND THE FIRST TOTAL SYNTHESIS OF (±)-ANABASAMINE AND RELATED ANALOGS A Dissertation Submitted to the Graduate Faculty of the University of New Orleans in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Department of Chemistry by Stassi C.
    [Show full text]
  • PMR 04-2005 00 Vstup+Obsah+Riljak.Pmd
    Prague Medical Report / Vol. 106 (2005) No. 4, p. 329–348 329) Nicotine an Efficient Tool of the Neurobiological Research Today, the Tool of Treatment Tomorrow? Riljak V., Langmeier M. Institute of Physiology of the First Faculty of Medicine, Charles University in Prague, Czech Republic Received November 28, 2005, Accepted December 9, 2005 Key words: Nicotine – Cholinergic receptors – Neurodegeneration – Neuroprotection This study was supported by grants GA ČR 305/03/H148 and GA UK 45/2004. Mailing Address: Vladimir Riljak, MD., Institute of Physiology of the First Faculty of Medicine, Charles University, Albertov 5, 120 28 Prague 2, Czech Republic Phone: +420 224 968 443, e-mail: [email protected] © Charles University in Prague – The Karolinum Press, Prague 2005 330) Prague Medical Report / Vol. 106 (2005) No. 4, p. 329–348 Abstract: Nicotine is a very widely used drug of abuse, which has many neurovegetative behavioural and psychological effects by interacting with neuronal nicotinic acetylcholine receptor. Cholinergic receptors can be divided into two types, muscarinic and nicotinic, based on the pharmacological action of various agonists and antagonists. This review summarises the major recent findings of nicotine effects in order to show the use of this drug in the neurophysiological research and namely as a potential tool for the treatment of some brain disorders. Introduction Cigarette smoke (CS) represents the source of nicotine, which can influence the activity of the central nervous system (CNS) [1, 2]. The pharmacological effects induced by CS are mediated mainly by (-)-nicotine [1]. Nicotine is a very widely used drug of abuse, which exerts a number of neurovegetative behavioural and psychological effects by interacting with neuronal nicotinic acetylcholine receptors (NAChR).
    [Show full text]
  • Identification of Novel α4β2-Nicotinic Acetylcholine Receptor (Nachr) Agonists Based on an Isoxazole Ether Scaffold That Demonstrate Antidepressant-Like Activity
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Barrow - St. Joseph's Scholarly Commons Barrow Neurological Institute at St. Joseph's Hospital and Medical Center Barrow - St. Joseph's Scholarly Commons Neurobiology 1-26-2012 Identification Of Novel α4β2-Nicotinic Acetylcholine Receptor (Nachr) Agonists Based On An Isoxazole Ether Scaffold That Demonstrate Antidepressant-Like Activity Li Fang Yu Werner Tuckmantel J. Brek Eaton Barbara Caldarone Allison Fedolak See next page for additional authors Follow this and additional works at: https://scholar.barrowneuro.org/neurobiology Recommended Citation Yu, Li Fang; Tuckmantel, Werner; Eaton, J. Brek; Caldarone, Barbara; Fedolak, Allison; Hanania, Taleen; Brunner, Dani; Lukas, Ronald J.; and Kozikowski, Alan P., "Identification Of Novel α4β2-Nicotinic Acetylcholine Receptor (Nachr) Agonists Based On An Isoxazole Ether Scaffold That Demonstrate Antidepressant-Like Activity" (2012). Neurobiology. 230. https://scholar.barrowneuro.org/neurobiology/230 This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been accepted for inclusion in Neurobiology by an authorized administrator of Barrow - St. Joseph's Scholarly Commons. For more information, please contact [email protected]. Authors Li Fang Yu, Werner Tuckmantel, J. Brek Eaton, Barbara Caldarone, Allison Fedolak, Taleen Hanania, Dani Brunner, Ronald J. Lukas, and Alan P. Kozikowski This article is available at Barrow - St. Joseph's Scholarly Commons: https://scholar.barrowneuro.org/neurobiology/ 230 Article pubs.acs.org/jmc Identification of Novel α4β2-Nicotinic Acetylcholine Receptor (nAChR) Agonists Based on an Isoxazole Ether Scaffold that Demonstrate Antidepressant-like Activity † § ‡ § § Li-Fang Yu, Werner Tückmantel, J.
    [Show full text]
  • A Convenient Synthetic Approach and Estimation of Their Affinity at Neuronal Nicotinic
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by AIR Universita degli studi di Milano Bioorganic & Medicinal Chemistry Letters 18 (2008) 4651–4654 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl Epiboxidine and novel-related analogues: A convenient synthetic approach and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes Luca Rizzi a, Clelia Dallanoce a,*, Carlo Matera a, Pietro Magrone a, Luca Pucci b, Cecilia Gotti b, Francesco Clementi b, Marco De Amici a a Istituto di Chimica Farmaceutica e Tossicologica ‘‘Pietro Pratesi”, Università degli Studi di Milano, Via Mangiagalli 25, 20133 Milano, Italy b CNR, Istituto di Neuroscienze, Farmacologia Cellulare e Molecolare e Dipartimento Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy article info abstract Article history: Racemic exo-epiboxidine 3, endo-epiboxidine 6, and the two unsaturated epiboxidine-related derivatives Received 18 June 2008 7 and 8 were efficiently prepared taking advantage of a palladium-catalyzed Stille coupling as the key Revised 3 July 2008 step in the reaction sequence. The target compounds were assayed for their binding affinity at neuronal Accepted 4 July 2008 a4b2 and a7 nicotinic acetylcholine receptors. Epiboxidine 3 behaved as a high affinity a4b2 ligand Available online 10 July 2008 (Ki = 0.4 nM) and, interestingly, evidenced a relevant affinity also for the a7 subtype (Ki = 6 nM). Deriva- tive 7, the closest analogue of 3 in this group, bound with lower affinity at both receptor subtypes Keywords: (K = 50 nM for a4b2 and K = 1.6 lM for a7) evidenced a gain in the a4b2 versus a7 selectivity when Neuronal nicotinic acetylcholine receptors i i compared with the model compound.
    [Show full text]